ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 94 Publications

17 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell Death Dis 2013 4, e801. ABT-737 purchased from Selleck.

    (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  NIXpbHFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MW[yOVAhdk4EoB?= M2TzZVczKGh? MXnEUXNQ MUPjZZV{\WRiOUelJIxwe3Nib3[geoli[mmuaYT5JIlvKGOnbHzzJJRz[W6|ZnXjeIVlKHerdHigRmNNPiC|aWLORS=> NX7NWHF1OjZ4NUeyPFg>
KG1a M1j5SGNmdGxiVnnhZoltcXS7IFHzd4F6 MojLNE0yOCEQvF2= M2LWblI1KGh? NWjifI4zTE2VTx?= NWXsRpFvUUN3ME23MlY5KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mn;mNlY2PTJ5MUK=
Kasumi-1 MnfsR4VtdCCYaXHibYxqfHliQYPzZZk> MkfDNE0yOCEQvF2= NFHpeVQzPCCq M4HIb2ROW09? MVHJR|UxRTRwOEeg{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGjYWG8zPjV3MkexNi=>
KG1a MULBdI9xfG:|aYOgRZN{[Xl? NGTi[GYxNTFyIN88US=> NWHw[nZTOjRiaB?= MkLFSG1UVw>? MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXWyOlU2OjdzMh?=
Kasumi-1 M2jrZ2Fxd3C2b4Ppd{BCe3OjeR?= MofWNE0yOCEQvF2= MorzNlQhcA>? NWG1cGpQTE2VTx?= NXLjUVBYcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4fVRlI3PTV{N{Gy
MC-3  MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TiXlUwOTBxMkCg{txO MWqyOEBp NFvYUFlFVVOR M1qy[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3;sb|I3PDR5NkG1
HN22  MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\TclIvPS95LkWvNlIvPSEQvF2= NGP3VJYzPCCq MUTEUXNQ MoTMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MkjqNlY1PDd4MUW=
MC-3  MlP6RZBweHSxc3nzJGF{e2G7 NYDEb3dzPS9zMD:yNEDPxE1? NGGxSJIzPCCq NW\sSoJqTE2VTx?= NFTBT5JqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz M2exfVI3PDR5NkG1
HN22  MWPBdI9xfG:|aYOgRZN{[Xl? MViyMlUwPy53L{KyMlUh|ryP M1nPSFI1KGh? M2TvcmROW09? MUTpcoR2[2W|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m| NIHqUYkzPjR2N{[xOS=>
MOLT-4 NFm0TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[2b|ExNTVyMECgcm0> NFT6XGE4OiCq MXvEUXNQ MlfmTWM2OD1yLkG5PEDPxE1? M4HmRVI3Ozl{M{Oy
RS4;11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxNE02ODByIH7N MkToO|IhcA>? NFjRfGJFVVOR NGPXcWxKSzVyPUCuNFAzKM7:TR?= NUToO3lJOjZ|OUKzN|I>
JURKAT NV[4O252T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTaeVgyOC13MECwJI5O MV23NkBp MWrEUXNQ NI\WOppKSzVyPU[2JO69VQ>? MlXoNlY{QTJ|M{K=
CEM R MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HRT|ExNTVyMECgcm0> MVm3NkBp Ml7LSG1UVw>? NXztOXlUUUN3ME21MlQh|ryP M1v0eVI3Ozl{M{Oy
CEM S M{HaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNE02ODByIH7N Mnr1O|IhcA>? Ml;USG1UVw>? MX3JR|UxRTF{LkGg{txO NXTrbXh{OjZ|OUKzN|I>
MOLT-4 M3zWXGFxd3C2b4Ppd{BCe3OjeR?= NGHCcHAyOC1zMECwJI5O NUHIOVF4OjRiaB?= NVvnNplGTE2VTx?= M1nVRoNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x MVmyOlM6OjN|Mh?=
CEM S NWLSVFVQSXCxcITvd4l{KEG|c3H5 MYGxNE0yODByIH7N NYWyfIY3OjRiaB?= NHX2bWpFVVOR MUDjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?= MkPaNlY{QTJ|M{K=
JURKAT MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zEfVExOC1zMECwJI5O MkPKOFghcA>? M3nKVGROW09? MkThTWM2OD17NUZCtVkvOyCwTR?= NXLYdJFEOjZzN{KyOlk>
LOUCY MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEftbXIyODBvMUCwNEBvVQ>? MWK0PEBp M1XM[2ROW09? NU\RW5dbUUN3ME2zNk45yrFzMD65JI5O Mln5NlYyPzJ{Nkm=
WM-115 MoD3R4VtdCCYaXHibYxqfHliQYPzZZk> M4i4O|ExOMLibl2= NHe2[VI4OiCq MUjlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>? M1K0SlI3OTF4N{e2
B16 Moi5R4VtdCCYaXHibYxqfHliQYPzZZk> MlnrNVAxyqCwTR?= M3P6V|czKGh? NV\q[JVG\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= NGfFfXIzPjFzNke3Oi=>
HL-60  M4DFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[1b2s4OiCq MYrJR|UxyqB;IEGwMlchdk1? M3TkV|I3ODR3NkC5
MOLM-13  M{fQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fjWVczKGh? NE\OOI9KSzVywrC9JFI4Njlibl2= NVu1T5FVOjZyNEW2NFk>
OCI-AML3 MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG3NkBp M{mwXmlEPTEEoE2gNVk2OCCwTR?= M{TUXFI3ODR3NkC5
BCWM.1 MV\BdI9xfG:|aYOgRZN{[Xl? MX:wMVEvPiEQvF2= MmXBNlQhcA>? MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NHrJRoIzPTh7M{K5NC=>
MWCL-1 NVGyR|FwSXCxcITvd4l{KEG|c3H5 MXuwMVEvPiEQvF2= M1e0TFI1KGh? NYPKZ3lRcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MX2yOVg6OzJ7MB?=
MM.1s M4TX[2Fxd3C2b4Ppd{BCe3OjeR?= NU\qbYRIOC1zLk[g{txO MlHWNlQhcA>? MmPTbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUGyOVg6OzJ7MB?=
HCT116 NVnlVYVNTnWwY4Tpc44hSXO|YYm= M1q5[|MwOTBizszN MXGxNuKhcMLi MV\EUXNQ NE[5ZmNqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hVEN|Qj3JTUBkd264ZYLzbY9vKGGwZDDTVXNVVTFiZHXndoFl[XSrb36= MmrLNlU4OTVyMki=
HCT116 BAX BAK1 DKO M1vXbmZ2dmO2aX;uJGF{e2G7 NUjNepViOy9zMDFOwG0> M3[weVEzyqCqwrC= MlH4SG1UVw>? M1fC[4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= M4PLN|I2PzF3MEK4
HCT116 NIXpNWVHfW6ldHnvckBCe3OjeR?= NIXBOm4yOCEQvF2= Mm\lNVLDqGkEoB?= Mo[zSG1UVw>? NIfXbm1qdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th MlLSNlU4OTVyMki=
HCT116 BAX BAK1 DKO M3XtNmZ2dmO2aX;uJGF{e2G7 MWWxNEDPxE1? NHPKdGIyOsLiaNMg MWHEUXNQ MXPpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj MnXyNlU4OTVyMki=
HCT116 MVTBeZRweGijZ4mgRZN{[Xl? NVrqeJVCOTBizszN NUPWPFV6OTMEoHlCpC=> NUjybJVpTE2VTx?= M{D4SYlv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm MW[yOVcyPTB{OB?=
HCT116 BAX BAK1 DKO NVvxbmVVSXW2b4DoZYd6KEG|c3H5 NUjv[GtVOTBizszN NIHzXWcyOsLiaNMg MYLEUXNQ NFXLNItqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>? MUOyOVcyPTB{OB?=
U937 MnfmRZBweHSxc3nzJGF{e2G7 MlnrNE4yOjVvMjFOwG0> NWTySmIxOjRiaB?= MY\lcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?= NEXUb2IzPTdzNECyOC=>
U937  MnrwRZBweHSxc3nzJGF{e2G7 NUPDT4pnOC53IN88US=> NFm3XYIzPCCq MW\lcohidmOnczDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMh[XNid3XscEBieyCQb4jhJIxmfmWu NEXqfYMzPTdzNECyOC=>
HL-60 AAA-Bcl-2 NXvjd2lJSXCxcITvd4l{KEG|c3H5 NV73eGdzOC13IN88US=> MWi0PEBp MVLJR|UxRTBwOEeg{txu97zOaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHjObIczPTdzMUS2NC=>
HL-60 EEE-Bcl-2 MWLBdI9xfG:|aYOgRZN{[Xl? MXywMVUh|ryP MUS0PEBp NUD2UFZPUUN3ME21JO69de,:jDDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVeyOVcyOTR4MB?=
U87 NFPK[mRHfW6ldHnvckBCe3OjeR?= NIXwNGw2OCEQvF2= MX[yOEBp NV3ZemhkemWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=> MnvKNlU3Pjd4NkO=
K562 M1vremNmdGxiVnnhZoltcXS7IFHzd4F6 MXyxMVExKM7:TR?= NYnjZ5NMPDhiaB?= M3HJPWROW09? M4jzW2lEPTB;Mk[uO{DPxE1? Mnq2NlU2QTZ3NkG=
K562/Mcl -1-IRESBim M3rXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrjeFhpUUN3ME25MlMh|ryP NYfIcWlvOjV3M{W5NFA>
K562/Bcl- 2-IRESBim MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwM{Wg{txO NFHUOoUzPTV|NUmwNC=>
Jurkat NEDq[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrCW3FKSzVyPUCuOlYh|ryP NXXjPHd2OjV3M{W5NFA>
JurkatΔBak NXexVVU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TGVWlEPTB-NUCg{txO NHz3[pkzPTV|NUmwNC=>
HL60/VCR MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33LXWlEPTB-MUCwJO69VQ>? NWnHe5NOOjV3M{W5NFA>
Kasumi-1 NH7M[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nZb2lEPTB;MD6wNUDPxE1? M2jwVlI2PTN3OUCw
Kasumi-1/ABT MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr0bYFKSzVyPUCuOVEh|ryP NUXkXYQ4OjV3M{W5NFA>
THP-1 NV7kTItzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwMkeg{txO MoqzNlU2OzV7MEC=
U937 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jRbmlEPTB;NT6yPUDPxE1? MlnCNlU2OzV7MEC=
C1498 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljZTWM2OD14LkGzJO69VQ>? NGHXRpEzPTV|NUmwNC=>
RPMI 8226 M3zwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[3SGh3UUN3ME2wMlI2KM7:TR?= MXuyOVU{PTlyMB?=
MM.1S MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwNECg{txO NVnwZYtyOjV3M{W5NFA>
NCI-H929 NFjMVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jxWGlEPTB;MUWuNlEh|ryP Ml:yNlU2OzV7MEC=
U266 NWrwenJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnUfplXUUN3ME2wMlY5KM7:TR?= M33DO|I2PTN3OUCw
MCF-7 MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NETxOnQ2KM7:TR?= MVe0PEBp NHHjSVFFVVOR M3X3TIVvcGGwY3XzJJRp\SC|ZX7zbZRqfmm2eTD0c{BweiC{YXTpZZRqd25? M2jFUVI2PDB7MUK0
MCF-7 M1XxcmFxd3C2b4Ppd{BCe3OjeR?= NHnNNHc2KM7:TR?= M2DFelQwOjRxNEigbC=> M{HOdmROW09? NYLROJRWcW6lcnXhd4V{KHSqZTDjcIVifmWmIGDBVnA> NYLEXIgxOjV2MEmxNlQ>
MCF-7 NH:2TZJHfW6ldHnvckBCe3OjeR?= NGnvWo02KM7:TR?= MofFNlQhcA>? M4\6SmROW09? M{ntRYVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? NVv1c|lKOjV2MEmxNlQ>
MDA-MB 231  NG\jOXBHfW6ldHnvckBCe3OjeR?= NVzjNYJyPSEQvF2= MnTxNlQhcA>? M2LqcWROW09? MUflcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> M13WZ|I2PDB7MUK0
ZR-75-1  MUjGeY5kfGmxbjDBd5NigQ>? NFq0RnI2KM7:TR?= NFK2PFAzPCCq M3PoPGROW09? Ml60[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh M33ERVI2PDB7MUK0
A549 NVfRWm5RS2WubDDWbYFjcWyrdImgRZN{[Xl? NVfGRZoxOC1{MDFOwG0> MWi3NkBp NWi0e2ppTE2VTx?= NEfye2tl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NI\LSZUzPTN6OEe2Ni=>
H1299 MmHaR4VtdCCYaXHibYxqfHliQYPzZZk> M{\aPFAuOjBizszN MY[3NkBp NIK5PZlFVVOR M{HiSYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? MYSyOVM5QDd4Mh?=
HO-8910 NFX3Z2hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3XoPVAuOjBizszN NF;zbpA4OiCq MXjEUXNQ NVz6[pRI\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= MXuyOVM5QDd4Mh?=
HT-29 M{\qXGNmdGxiVnnhZoltcXS7IFHzd4F6 M{myRVAuOjBizszN NH6zbno4OiCq MXrEUXNQ MmPm[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NVTpbFN6OjV|OEi3OlI>
HCT-116 NV22[FVmS2WubDDWbYFjcWyrdImgRZN{[Xl? NFroOosxNTJyIN88US=> M3HzZVczKGh? NIXoe2RFVVOR MUTk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv M1XRN|I2Ozh6N{[y
A549 NXHse4VzSXCxcITvd4l{KEG|c3H5 MXeyNEDPxE1? NFPxO|E1QCCq NVy4OYZCTE2VTx?= NVOyUmoycW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG|cHnybY4> Mn6wNlU{QDh5NkK=
H1299 M3PGXmFxd3C2b4Ppd{BCe3OjeR?= MkHONlAh|ryP NVTnPHlKPDhiaB?= M3\wRWROW09? MVHpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= MlHmNlU{QDh5NkK=
Sc-1 NF3hcW9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGG5UncxNjByMEGtNUDPxE1? MXe5OkBp NU\UPItV\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mo\sNlU{PzN3MEi=
OcI-LY18 M1e4eWNmdGxiVnnhZoltcXS7IFHzd4F6 M2OyV|AvODByMT2xJO69VQ>? NH7VfVc6PiCq NWTic3FF\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFvQNoUzPTN5M{WwPC=>
RL  NG\wUHlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVuwMlAxODFvMTFOwG0> M2GyW|k3KGh? M2ntcYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlW4NlU{PzN3MEi=
RKO M2n0[2NmdGxiVnnhZoltcXS7IFHzd4F6 NGLIR4gxNTFyIN88US=> MkjBNlTjiImqwrC= NFXkcGdFVVOR MXvJR|UxRuLCiUK15qCKyrWP M3fvSlI2OzB2M{iz
Caco-2 NHm2ZlhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUCwMVExKM7:TR?= MVKyOQKBkWkEoB?= M3HJVmROW09? NEWxe|JKSzVyPUG5MlfjiIoEtV2= MmH4NlU{ODR|OEO=
DLD1 M1nMXmNmdGxiVnnhZoltcXS7IFHzd4F6 NHjHflExNTFyIN88US=> MV:yOQKBkWkEoB?= NXrXTmE4TE2VTx?= MnnhTWM2OD1zOD63PQKBkcL3TR?= Mli2NlU{ODR|OEO=
LS411N M4TVeGNmdGxiVnnhZoltcXS7IFHzd4F6 NEG5bHQxNTFyIN88US=> MlHONlTjiImqwrC= Mm\0SG1UVw>? NYLyd3E5UUN3ME2xNU41P+LCidM1US=> MUOyOVMxPDN6Mx?=
SW620 NFP1eZFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlH6NE0yOCEQvF2= NX7LN2tiOjUkgJnoxsA> NILuXXZFVVOR MmfOTWM2OD1zMj6yOQKBkcL3TR?= M3rhPVI2OzB2M{iz
HCT116 NYjIdpZmS2WubDDWbYFjcWyrdImgRZN{[Xl? NHPpUYoxNTFyIN88US=> NITVSYYzPOLCiXlCpC=> NUTkeI92TE2VTx?= M{TDUWlEPTB;MkCuOFnjiIoEtV2= MYCyOVMxPDN6Mx?=
HaCaT NVLiRXVqS2WubDDWbYFjcWyrdImgRZN{[Xl? NEDqcIMxNjFxMT:xNEDPxE1? M4K3VFI1KGh? M16zSGROW09? NXrBNI5W\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHrLVYkzPTJzMEe5OS=>
A5-RT3 NUPqPXV2S2WubDDWbYFjcWyrdImgRZN{[Xl? MVGwMlEwOS9zMDFOwG0> MXWyOEBp MlrFSG1UVw>? M1G5ZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnXRNlUzOTB5OUW=
HaCaT NEPt[3VHfW6ldHnvckBCe3OjeR?= MYixNQKBkc7:TR?= MWGyOE81QCCq NH2wXWJFVVOR MVvpcoR2[2W|IF3NVEBidmRiRF7BJIZz[WevZX70ZZRqd25? M33yT|I2OjFyN{m1
A5-RT3 MWfGeY5kfGmxbjDBd5NigQ>? M17jeFEx6oDLzszN MonNNlQwPDhiaB?= NEjsSllFVVOR MV7pcoR2[2W|IF3NVEBidmRiRF7BJIZz[WevZX70ZZRqd25? M1S4R|I2OjFyN{m1
A5-RT3 NVzaO|JlTnWwY4Tpc44hSXO|YYm= NVzaXXBnPSEQvF2= M1njVlYhcA>? MUXEUXNQ MXPpcoR2[2W|IITo[UBz\WynYYPlJI9nKG2rdH;jbI9v\HKrYXygdJJwfGWrboOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJINie3Cjc3WtbY5l\XCnbnTlcpQhdWGwbnXy MWqyOVIyODd7NR?=
U266 NYHuU2x7TnWwY4Tpc44hSXO|YYm= NFjHb5c2ODBxN{WwJI5O Mn;SNlQwPDhiaB?= MlfjSG1UVw>? M{fubYRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> NWn5NXc{OjV{MEi4PFg>
RPMI8226 M2Xvc2Z2dmO2aX;uJGF{e2G7 M4XBO|UxOC95NUCgcm0> NILqRnYzPC92ODDo NHv0NJZFVVOR MXvkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= NFv3VWQzPTJyOEi4PC=>
MM.1S MnLiSpVv[3Srb36gRZN{[Xl? NXPJ[lFCPTByL{e1NEBvVQ>? MUiyOE81QCCq NHvMUWVFVVOR MnvV[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt M2nLSFI2OjB6OEi4
Clone A MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4raOVAvOuLCk{[wJO69VQ>? M1fmPFczKGh? M3vYfGROW09? MkXITWM2OD15LkWg{txO NU\LVY42OjV{MEi4PFI>
CX-1 NWD4dFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPVW2MxNjMkgKO2NEDPxE1? NWP4TVI4PzJiaB?= MkHuSG1UVw>? NVPLVI5CUUN3ME2xMlgh|ryP NVPVfFdEOjV{MEi4PFI>
LS174T NV\5bnUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInidFQxNjMkgKO2NEDPxE1? NYjPeoF[PzJiaB?= MmHKSG1UVw>? M{LMWWlEPTB;MUiuN{DPxE1? Mn:5NlUzODh6OEK=
HT29 MUPBdI9xfG:|aYOgRZN{[Xl? NXXSUW1sOS93L{GwJO69VQ>? MUK0PEBp MVjjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NE\RSmozPTF7MkG4PC=>
SW480 NGflUIFCeG:ydH;zbZMhSXO|YYm= NVLYelNZOS93L{GwJO69VQ>? M4\MRVQ5KGh? MnrlZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MV2yOVE6OjF6OB?=
Colo205 M1;aeGFxd3C2b4Ppd{BCe3OjeR?= NF\LeWoyNzVxMUCg{txO MUe0PEBp MW\jZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4fBU|I2OTl{MUi4
Caco2 MX\BdI9xfG:|aYOgRZN{[Xl? MljMNU82NzFyIN88US=> NXnhb|NPPDhiaB?= MYDjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MX[yOVE6OjF6OB?=
PCI-13 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS2NlhnPzJiaB?= M4nlO2ROW09? MmPDS2k2OD1zNTFCtUAyNjhizszN M2KxXlI2OTN7M{i3
PCI-15B M1TSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfrVlBHPzJiaB?= M1\1W2ROW09? NIHnSZZIUTVyPUGxJOKyKDRwNTFOwG0> M2LGbVI2OTN7M{i3
UM-SCC22B MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKzSng4OiCq NV31Z3Z1TE2VTx?= Mo[4S2k2OD1zOTFCtUAzNjlizszN NYnOVYZUOjVzM{mzPFc>
UM-SCC47 M2e1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG2O|IhcA>? MYjEUXNQ MYDHTVUxRTF7INMxJFEzNjNizszN NV3G[IZbOjVzM{mzPFc>
93-VU-147T NG[zdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXvbVRYPzJiaB?= MVLEUXNQ NF\hNIlIUTVyPUSuN{DDuSB|LkWg{txO NFu4Z5czPTF|OUO4Oy=>
UD-SCC2 M3rrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjLSHYyPzJiaB?= MkfESG1UVw>? M2DwdmdKPTB;MkigxtEhOi57IN88US=> M3vsb|I2OTN7M{i3
UPCI:SCC90 NGLmbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LpXFczKGh? M3L2OWROW09? M3jPVmdKPTB;Nj62JOKyKDFwNTFOwG0> NFzHVGozPTF|OUO4Oy=>
RPMI-8226  NUnrXG5WS2WubDDWbYFjcWyrdImgRZN{[Xl? M2TCU|EzPS9{NUCvOVAxKG6P NF7yNZA1QGkEoB?= MmnaSG1UVw>? MYLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlvENlUxODh{MEK=
OPM-2  NXvsZWlCS2WubDDWbYFjcWyrdImgRZN{[Xl? NV;zdJFIOTJ3L{K1NE82ODBibl2= NVSyW2lVPDiqwrC= NFjMcWpFVVOR MUPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2POVlI2ODB6MkCy
RPMI-8226  M4LmOmFxd3C2b4Ppd{BCe3OjeR?= NYHXNpJEOTJ3L{K1NE82ODBibl2= NEjIfo41QGkEoB?= NWnue29PTE2VTx?= Mm\IbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlvRNlUxODh{MEK=
OPM-2  NE\6R4NCeG:ydH;zbZMhSXO|YYm= M{HYZ|EzPS9{NUCvOVAxKG6P NYK1SYhEPDiqwrC= M2PW[WROW09? MlXVbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUWyOVAxQDJyMh?=
COG-LL-319 MXLGeY5kfGmxbjDBd5NigQ>? NXns[IVJOTByIH7N NFfYOJkyNzNxNjDo NEnuU5BFVVOR NFOxOJhqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen M2TRfVI1QTVzNEey
RS4;11 M{fuS2Z2dmO2aX;uJGF{e2G7 Mn61NVAxKG6P MXKxM|MwPiCq MoHaSG1UVw>? NIjjV|VqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen NUO2XotWOjR7NUG0O|I>

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID